实用医学杂志2011，Vol.27Issue(11)：2024-2026,3.DOI:10.3969/j.issn.1006-5725.2011.11.051
罗格列酮对早期糖尿病肾病脂联素的影响
Effects of rosiglitazone on the expression of adiponectin in early diabetic nephropathy
摘要
Abstract
Objective To investigate the effects of rosiglitazone on the expression of adiponectin in early diabetic nephropathy. Methods Eighty patients with type 2 diabetes and early diabetic nephropathy were randomly divided into two groups: rosiglitazone group (n = 40) and control group (n= 40). Patients in rosiglitazone group received rosiglitazone 4 mg/d and other treatment of lowering blood glucose while those in control group were treated without rosiglitazone. The fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPG), HbAlc, fasting insulin (Fins), high sensitive C-reactive protein (hsCRP), adiponectin (APN), urine microalbumin (MA), and urine creatinine (UCr) were measured before and 12 weeks after treatment. Results The FBG, 2hPG, HbAlc, Fins, HOMA-IR, and urine albumin excretion ratio (UAER)were significantly decreased in the two groups after treatment (P ＜ 0.05). HOMA-IR and UAER were decreased significantly in rosiglitazone group than those in control group (P ＜ 0.05). The level of hsCRP was decrased significantly (P ＜ 0.05), while the concentration of APN was increased significantly (P ＜ 0.05) in rosiglitazone group after treatment, but were not changed in control group. Conclusion Rosiglitazone may play a protective role in diabetic nephropathy by inhibiting inflammatory response.关键词
糖尿病肾病/罗格列酮/脂联素Key words
Diabetic nephropathy/ Rosiglitazone/ Adiponectin引用本文复制引用
舒毅,陈幼萍,曾春平,潘苗,罗少(荘)..罗格列酮对早期糖尿病肾病脂联素的影响[J].实用医学杂志,2011,27(11):2024-2026,3.基金项目
佛山市卫生局科研立项(编号:2009203) （编号:2009203）
